Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05642962 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05642962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05642962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 30, 2022
Completion date
November 30, 2026
Enrollment
17 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma, metastatic pancreatic cancer, metastatic pancreatic carcinoma, metastatic pancreatic ductal adenocarcinoma, pancreatic cancer, pancreatic cancer metastatic, pancreatic cancer non-resectable, pancreatic cancer stage iv, pancreatic carcinoma, pancreatic carcinoma metastatic, pancreatic carcinoma non-resectable, pdac, pdac - pancreatic ductal adenocarcinoma